S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

$115.61
+0.11 (+0.10%)
(As of 09/22/2023 ET)
Compare
Today's Range
$115.51
$115.73
50-Day Range
$98.98
$115.61
52-Week Range
$60.03
$115.73
Volume
1.64 million shs
Average Volume
3.79 million shs
Market Capitalization
$26.47 billion
P/E Ratio
61.82
Dividend Yield
N/A
Price Target
$110.71

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.2% Downside
$110.71 Price Target
Short Interest
Bearish
4.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
1.44mentions of Horizon Therapeutics Public in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
42.19%
From $4.29 to $6.10 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

663rd out of 967 stocks

Pharmaceutical Preparations Industry

295th out of 441 stocks


HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

HZNP Price History

HZNP Stock News Headlines

3 Growth Stocks to Buy in September (HZNP)
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (HZNP)
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Improved Outlook For Horizon Therapeutics And Amgen
Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright
Amgen raises full-year earnings and revenue outlook
Check Out What Whales Are Doing With HZNP
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
8/08/2023
Today
9/23/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
2,115
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$110.71
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
-4.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$521.48 million
Pretax Margin
12.18%

Debt

Sales & Book Value

Annual Sales
$3.64 billion
Cash Flow
$7.06 per share
Book Value
$22.38 per share

Miscellaneous

Free Float
223,957,000
Market Cap
$26.47 billion
Optionable
Optionable
Beta
1.05

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Timothy P. WalbertMr. Timothy P. Walbert (Age 56)
    Chairman, Pres & CEO
    Comp: $3.5M
  • Mr. Aaron L. CoxMr. Aaron L. Cox (Age 40)
    Exec. VP of Fin. & CFO
    Comp: $1.36M
  • Mr. Sean M. Clayton J.D.Mr. Sean M. Clayton J.D. (Age 44)
    Exec. VP & Gen. Counsel
    Comp: $7.03M
  • Mr. Andy PasternakMr. Andy Pasternak (Age 52)
    Exec. VP & Chief Strategy Officer
    Comp: $1.4M
  • Dr. Elizabeth H.Z. Thompson Ph.D.Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)
    Exec. VP of R&D
    Comp: $3.66M
  • Mr. Patrick McIlvenny (Age 44)
    Sr. VP & Chief Accounting Officer
  • Ms. Tina E. Ventura
    Sr. VP & Chief Investor Relations Officer
  • Mr. Geoffrey M. CurtisMr. Geoffrey M. Curtis (Age 48)
    Exec. VP of Corp. Affairs & Chief Communications Officer
  • Ms. Keli Walbert
    Exec. VP & Chief Marketing Officer
  • Ms. Jane Gonnerman
    Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO













HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2023?

8 analysts have issued 1 year price objectives for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $74.00 to $125.00. On average, they predict the company's share price to reach $110.71 in the next year. This suggests that the stock has a possible downside of 4.2%.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2023?

Horizon Therapeutics Public's stock was trading at $113.80 on January 1st, 2023. Since then, HZNP stock has increased by 1.6% and is now trading at $115.61.
View the best growth stocks for 2023 here
.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 20.6% from the August 15th total of 7,860,000 shares. Based on an average daily volume of 2,300,000 shares, the days-to-cover ratio is currently 4.1 days.
View Horizon Therapeutics Public's Short Interest
.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our HZNP earnings forecast
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) released its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. Horizon Therapeutics Public's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.07 earnings per share.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.51%), Bluefin Capital Management LLC (0.00%), State Street Corp (2.30%), Maven Securities LTD (0.00%), Renaissance Technologies LLC (1.51%) and Soros Fund Management LLC (1.44%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $115.61.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $26.47 billion and generates $3.64 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.87 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 2,115 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -